Sugi Predict

Sugi Predict / Compounds / SCHEMBL6728919

SCHEMBL6728919

SCHEMBL6728919

NS(=O)(=O)c1c(F)cc(-c2csc(=O)n2-c2cccc(Cl)c2)cc1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGS2 P35354 4/20 0.43
▸ PTGS1 P23219 1/20 0.43
▸ CA12 O43570 6/20 0.38
▸ CA1 P00915 6/20 0.38
▸ CA2 P00918 6/20 0.38
▸ CA9 Q16790 6/20 0.38
▸ ALDH1A1 P00352 2/20 0.37
▸ PTGES2 Q9H7Z7 2/20 0.37
▸ MAPT P10636 1/20 0.34
▸ RGS4 P49798 1/20 0.33
▸ RGS8 P57771 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ FLT3 P36888 1/20 0.33
▸ KDR P35968 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6737335 0.89 CA1 (0.36) PTGS2PTGS1CA12CA1CA2
SCHEMBL6739760 0.88 PTGS2 (0.41) PTGS2PTGS1CA12CA1CA2
SCHEMBL6732474 0.88 CA1 (0.33) PTGS2PTGS1CA12CA1CA2
SCHEMBL6740773 0.87 CA1 (0.39) PTGS2PTGS1CA12CA1CA2
SCHEMBL6734798 0.87 CA1 (0.38) PTGS2PTGS1CA12CA1CA2
SCHEMBL6725791 0.86 PTGS2 (0.44) PTGS2PTGS1CA12CA1CA2
SCHEMBL6737317 0.86 PTGS2 (0.43) PTGS2PTGS1CA12CA1CA2
SCHEMBL6729121 0.85 GAA (0.38) CA12CA1CA2CA9ALDH1A1
SCHEMBL6729254 0.84 CA1 (0.37) PTGS2PTGS1CA12CA1CA2
SCHEMBL6729677 0.84 CA1 (0.37) PTGS2PTGS1CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6699884-B2 ANTIINFLAMMATORY CYCLOOXYGENASE INHIBITORS. PHARMACIA CORPORATION 2004-03-02 — — US claimed
US-20040138261-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2004-07-15 — — US disclosed
US-6699884-B2 ANTIINFLAMMATORY CYCLOOXYGENASE INHIBITORS. PHARMACIA CORPORATION 2004-03-02 — — US disclosed
US-6673818-B2 TREATING CYCLOOXYGENASE-2 MEDIATED DISORDERS, SUCH AS ARTHRITIS, PAIN, FEVER AND CANCER PHARMACIA CORPORATION 2004-01-06 — — US disclosed
US-20030149078-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2003-08-07 — — US disclosed
US-20030032657-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2003-02-13 — — US disclosed
EP-1251126-A2 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation Pharmacia Corporation (US) 2002-10-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138261-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 PTGS2 10/4885PTGS1 4/4885CA12 4391/4885
US-20030149078-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 PTGS2 10/4885PTGS1 4/4885CA12 4391/4885
US-20030032657-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 PTGS2 10/4885PTGS1 4/4885CA12 4391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.